Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31387892 | 1.00 | MAOB (0.48) | MAOBPKMKMT2AHSD17B10NR1H4 | |
| SCHEMBL6180535 | 0.83 | MAOB (0.51) | MAOBPKMPOLBALDH1A1L3MBTL1 | |
| SCHEMBL24329491 | 0.81 | PKM (0.59) | MAOBPKMKMT2APOLBALDH1A1 | |
| SCHEMBL11810092 | 0.81 | NR1H4 (0.45) | MAOBNR1H4EPHX2SRC | |
| SCHEMBL14156904 | 0.81 | DPP4 (0.48) | KMT2AHSD17B10NR1H4EPHX2MEN1 | |
| SCHEMBL11039596 | 0.81 | ERN1 (0.40) | MAOBNR1H4EPHX2ALDH1A1SRC | |
| SCHEMBL14368281 | 0.80 | NR1H4 (0.55) | MAOBPKMKMT2AHSD17B10NR1H4 | |
| SCHEMBL28778368 | 0.80 | MAPK1 (0.58) | MAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL23216021 | 0.79 | CA12 (0.51) | KMT2AHSD17B10MEN1POLBALDH1A1 | |
| SCHEMBL29843822 | 0.79 | CA12 (0.51) | KMT2AHSD17B10MEN1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391794-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | CENTURION BIOPHARMA CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-11572373-B2 | Maytansinoid-based drug delivery systems | LADRX CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-20200385403-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | LADRX CORPORATION | 2020-12-10 | — | — | US | disclosed |
| EP-3717018-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | Centurion BioPharma Corporation (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111712263-A | Maytansinoid-based drug delivery system | 森托瑞恩生物制药公司 | 2020-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391794-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | SLC6A2, SLC6A7, SLC6A4 | MAOB 894/4885PKM 2622/4885KMT2A 4652/4885 |
| US-20200385403-A1 | MAYTANSINOID-BASED DRUG DELIVERY SYSTEMS | SLC6A2, SLC6A7, SLC6A4 | MAOB 894/4885PKM 2622/4885KMT2A 4652/4885 |
| US-11572373-B2 | Maytansinoid-based drug delivery systems | SLC6A2, SLC6A7, SLC6A4 | MAOB 894/4885PKM 2622/4885KMT2A 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.